Yüklüyor......
N‐glycosylation of PD‐1 promotes binding of camrelizumab
PD‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD‐1 with monoclonal antibodies (MAbs) to block the interaction with its ligand PD‐L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N‐glycosylation sites of PD‐1 exist in...
Kaydedildi:
| Yayımlandı: | EMBO Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7726772/ https://ncbi.nlm.nih.gov/pubmed/33063473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.202051444 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|